Pfizer, Allergan To Merge In $160B Deal
U.S. pharmaceutical giant Pfizer said Monday it will combine with Irish drugmaker Allergan in a stock-for-stock deal valued at $160 billion, a deal that comes despite heightened scrutiny of inversion transactions....To view the full article, register now.
Already a subscriber? Click here to view full article